Marilyn’s Message

RSS feed for this section

Marilyn’s Message July 2017

Marilyn Geller

After decades of research and the investment of tens of millions of dollars, there are no approved treatments for celiac disease beyond strict adherence to a gluten-free diet. The single best chance for changing this is iCureCeliac®. Your gifts last year helped us expand and improve this revolutionary research resource. Below is a brief accounting […]

Marilyn’s Message April 2017

Marilyn Geller

In honor of May Celiac Awareness Month, Celiac Disease Foundation (CDF) and the Gluten Intolerance Group (GIG) are proud to announce a partnership that will improve the health and well-being of the celiac disease and gluten-free communities. In order to create the most comprehensive nonprofit source of education, research, advocacy, social networking, and support for […]

Marilyn’s Message February 2017

Marilyn Geller

Celiac disease research is desperately underfunded. The primary reason that celiac disease research has historically been underfunded relative to other diseases with similar population prevalence and impact is the assumption that lifetime adherence to a strict, gluten-free diet effectively manages the disease. We know now that this assumption is definitely not true for many in our community… and may not […]

Marilyn’s Message January 2017

Marilyn Geller

Elaine Monarch founded Celiac Disease Foundation to give voice to the millions of celiac disease sufferers who were being systematically ignored by doctors, medical researchers, and our government.  A major part of our work over the last 30 years has been advocacy, including a successful campaign to secure gluten-free labeling regulations. Today, I am writing to […]

Marilyn’s Message December 2016

Marilyn Geller

2016 has been another milestone year for Celiac Disease Foundation. We began the year launching the revolutionary iCureCeliac® patient registry, the cornerstone of a systematic and cooperative approach between academia, private industry, and patient advocates to apply the principals of precision medicine to developing treatments and a cure for celiac disease. Over the course of […]

Marilyn’s Message October 2016

Marilyn Geller

This month, Celiac Disease Foundation launched the Pediatric and Adult Celiac Disease Follow-up Checklists. Based upon recommendations from the world’s leading medical experts, the Follow-Up Checklists specify best practices in post-diagnosis celiac disease management to assure optimal patient care.

Marilyn’s Message August 2016

Marilyn Geller

If you are a parent, you know how challenging the entire back-to-school process can be. Now, imagine that your child has celiac disease or non-celiac wheat sensitivity (NCWS). Currently, parents are confronting the reality of sending their gluten-free children back to school, and I know from experience just how intimidating and frustrating it can be. Our first […]

Marilyn’s Message July 2016

Marilyn Geller

Last month, we shared the statistics from the first 1,200 participants in iCureCeliac®. Our first cut of analysis revealed interesting and, quite frankly, potentially alarming numbers about celiac disease, such as: 33 percent of iCureCeliac® participants reported that diagnosis took longer than five years from the onset of their first symptoms. 53 percent of iCureCeliac® […]

Marilyn’s Message June 2016

Marilyn Geller

Having a child diagnosed with a chronic autoimmune disease can be very scary. When Gabbi Saft was diagnosed with celiac disease, her parents, Warren and Amber, turned to the Celiac Disease Foundation (CDF) to begin researching the challenges that she would face. What they learned was that every time she had a school lunch, went […]

Marilyn’s Message May 2016

Marilyn Geller

Thank you to our more than 1,000 iCureCeliac participants for your amazing commitment to help researchers advance treatments and a cure for celiac disease and gluten sensitivity. I am pleased to share with you that we already have two research studies in place! The first is with Celimmune who is sponsoring clinical trials to test a drug […]